We are live on
!
Find out more
PM
Prosight Management Portfolio holdings
AUM
$610M
1-Year Est. Return
40.86%
This Fund
S&P 500
This Quarter
Est. Return
-7.7%
1 Year Est. Return
+40.86%
3 Year Est. Return
+46.17%
5 Year Est. Return
+1.2%
10 Year Est. Return
–
AUM
$211M
AUM Growth
+$27.6M
(+15%)
Cap. Flow
+$53.8M
Cap. Flow
% of AUM
25.48%
Top 10 Holdings %
Top 10 Hldgs %
55.57%
Holding
55
New
15
Increased
12
Reduced
13
Closed
14
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Centene
CNC
|
+$11.5M |
| 2 |
ADC Therapeutics
ADCT
|
+$10.3M |
| 3 |
BioCryst Pharmaceuticals
BCRX
|
+$9.22M |
| 4 |
KZR
Kezar Life Sciences
KZR
|
+$8.36M |
| 5 |
Neurocrine Biosciences
NBIX
|
+$8.32M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALBO
Albireo Pharma Inc
ALBO
|
+$10.5M |
| 2 |
TriNet
TNET
|
+$5.29M |
| 3 |
Health Catalyst
HCAT
|
+$3.7M |
| 4 |
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
|
+$3.68M |
| 5 |
Aldeyra Therapeutics
ALDX
|
+$3.36M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.96% |
| 2 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Erasca
ERAS
$6.63B
| $3.55M | 1.68% |
+1,179,090
| New | +$4.29M |
|
27
Compass Therapeutics
CMPX
$373M
| $2.22M | 1.05% |
+678,300
| New | +$2.66M |
|
|
LENZ
28
LENZ Therapeutics
LENZ
$172M
| $2.15M | 1.02% |
125,238
-5,699
| -4% | -$92.2K |
|
|
KALV
29
DELISTED
KalVista Pharmaceuticals
KALV
| $1.89M | 0.89% |
240,000
-381,667
| -61% | -$2.85M |
|
|
LKFT
30
CALL
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.82B
| $1.55M | 0.73% |
40,000
| – | – |
|
|
MODV
31
DELISTED
ModivCare
MODV
| $1.3M | 0.62% |
+15,452
| New | +$1.49M |
|
32
Teladoc Health
TDOC
$1.58B
| $1.19M | 0.56% |
+45,900
| New | +$1.23M |
|
|
KZR
33
CALL
DELISTED
Kezar Life Sciences
KZR
| $626K | 0.3% |
+20,000
| New | +$1.16M |
|
34
Insmed
INSM
$23.2B
| $449K | 0.21% |
+26,359
| New | +$512K |
|
|
TSVT
35
DELISTED
2seventy bio
TSVT
| $434K | 0.21% |
+42,537
| New | +$486K |
|
|
MORF
36
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $319K | 0.15% |
8,464
-34,485
| -80% | -$1.27M |
|
37
Elutia
ELUT
$41.1M
| $297K | 0.14% |
196,443
+11,429
| +6% | +$43.8K |
|
38
BridgeBio Pharma
BBIO
$16.5B
| $216K | 0.1% |
13,000
-76,027
| -85% | -$887K |
|
39
The Oncology Institute
TOI
$498M
| $191K | 0.09% |
281,902
+6,341
| +2% | +$8.09K |
|
40
Lifestance Health
LFST
$4.16B
| $66.9K | 0.03% |
9,000
-280,335
| -97% | -$1.55M |
|
41
State Street SPDR S&P Biotech ETF
XBI
$10.1B
| $20.8K | 0.01% |
+273
| New | +$22.7K |
|
42
Biomea Fusion
BMEA
$90.4M
| – | – |
-81,907
| Closed | -$690K |
|
43
Evolus
EOLS
$394M
| – | – |
-66,438
| Closed | -$499K |
|
44
Gossamer Bio
GOSS
$66.5M
| – | – |
-265,000
| Closed | -$575K |
|
|
45
Health Catalyst
HCAT
$154M
| – | – |
-347,724
| Closed | -$3.7M |
|
46
Intellia Therapeutics
NTLA
$1.5B
| – | – |
-72,116
| Closed | -$2.52M |
|
47
Personalis
PSNL
$1.26B
| – | – |
-58,668
| Closed | -$116K |
|
48
Rocket Pharmaceuticals
RCKT
$348M
| – | – |
-32,193
| Closed | -$630K |
|
|
FLNA
49
PUT
Filana Therapeutics
FLNA
$43M
| – | – |
-40,900
| Closed | -$1.21M |
|
|
50
TriNet
TNET
$2.84B
| – | – |
-78,000
| Closed | -$5.29M |
|
Similar funds
PL
BFC
DCM
SAM
CBB
AIG
FFWA
CIP
Prosight Management's Q1 2023 Portfolio in Review
As of Q1 2023, Prosight Management held 55 positions worth $211M, up 15% from $183M the previous quarter. Its ten largest holdings account for 56% of the portfolio.
Prosight Management deployed $53.8M of net new capital in Q1 2023, opening 15 new positions and adding to 12 existing holdings. Its largest new stake was Centene: 161,404 shares worth $10.2M.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 94% a quarter earlier, followed by Industrials.
On the sell side, the largest reduction was Lakefront Biotherapeutics American Depositary Shares, an estimated $3.68M trimmed.
- Prosight Management's largest Q1 2023 buy was Centene: 161,404 shares worth $10.2M.
- Prosight Management added most to ADC Therapeutics in Q1 2023, an estimated $10.3M increase.
- Prosight Management's biggest Q1 2023 reduction was Lakefront Biotherapeutics American Depositary Shares, cutting an estimated $3.68M.
- Prosight Management fully exited Albireo Pharma Inc in Q1 2023, selling an estimated $10.5M.
- Prosight Management's ten largest holdings make up 56% of its $211M portfolio in Q1 2023.
- Prosight Management opened 15 new positions and closed 14 in Q1 2023.
- Prosight Management's portfolio value rose 15% quarter-over-quarter to $211M.
Based on Prosight Management's 13F filing for Q1 2023, filed 12 May 2023.